A Khanna1, R Gish2, S C Winter3, W L Nyhan4, B A Barshop5. 1. Department of Surgery and Center for Gut Rehabilitation and Transplantation, Transplant Center, Cleveland Clinic, Cleveland, OH, 44195, USA. 2. Department of Gastroenterology, Stanford University, Palo Alto, CA, 94305, USA. 3. Department of Genetics, Children's Hospital of Central California, Madera, CA, 93636, USA. 4. Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, CA, 92093-0830, USA. 5. Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, CA, 92093-0830, USA. bbarshop@ucsd.edu.
Abstract
Liver transplantation has been reported in patients with methylmalonic acidemia (MMA), but long-term outcome is controversial. Many patients with other approved indications for liver transplantation die before donor grafts are available. A 28-year-old man with MMA underwent cadaveric liver transplantation. His liver was used as a domino graft for a 61-year-old man with primary sclerosing cholangitis, who had low priority on the transplant waiting list. Surgical outcome was successful, and after transplantation both patients have excellent graft function. The patient with MMA showed substantial decrease in methylmalonate in urine (from 5,277 ± 1,968 preoperatively to 1,068 ± 384 mmol/mol creatinine) and plasma (from 445.9 ± 257.0 to 333.3 ± 117.7 μmol/l) over >1-year follow-up, while dietary protein intake increased from 0.6 to 1.36 ± 0.33 g/kg/day. The domino recipient maintained near-normal levels of plasma amino acids but did develop elevated methylmalonate in blood and urine while receiving an unrestricted diet (peak plasma methylmalonate 119 μmol/l and urine methylmalonate 84-209 mmol/mol creatinine, with 1.0-1.9 g/kg/day protein). Neither patient demonstrated any apparent symptoms of MMA or metabolic decompensation during the postoperative period or following discharge. CONCLUSION: Liver transplantation substantially corrects methylmalonate metabolism in MMA and greatly attenuates the disease. In this single patient experience, a liver from a patient with MMA functioned well as domino graft although it did result in subclinical methylmalonic acidemia and aciduria in the recipient. Patients with MMA can be considered as domino liver donors for patients who might otherwise spend long times waiting for liver transplantation.
Liver transplantation has been reported in patients with methylmalonic acidemia (MMA), but long-term outcome is controversial. Many patients with other approved indications for liver transplantation die before donor grafts are available. A 28-year-old man with MMA underwent cadaveric liver transplantation. His liver was used as a domino graft for a 61-year-old man with primary sclerosing cholangitis, who had low priority on the transplant waiting list. Surgical outcome was successful, and after transplantation both patients have excellent graft function. The patient with MMA showed substantial decrease in methylmalonate in urine (from 5,277 ± 1,968 preoperatively to 1,068 ± 384 mmol/mol creatinine) and plasma (from 445.9 ± 257.0 to 333.3 ± 117.7 μmol/l) over >1-year follow-up, while dietary protein intake increased from 0.6 to 1.36 ± 0.33 g/kg/day. The domino recipient maintained near-normal levels of plasma amino acids but did develop elevated methylmalonate in blood and urine while receiving an unrestricted diet (peak plasma methylmalonate 119 μmol/l and urine methylmalonate 84-209 mmol/mol creatinine, with 1.0-1.9 g/kg/day protein). Neither patient demonstrated any apparent symptoms of MMA or metabolic decompensation during the postoperative period or following discharge. CONCLUSION: Liver transplantation substantially corrects methylmalonate metabolism in MMA and greatly attenuates the disease. In this single patient experience, a liver from a patient with MMA functioned well as domino graft although it did result in subclinical methylmalonic acidemia and aciduria in the recipient. Patients with MMA can be considered as domino liver donors for patients who might otherwise spend long times waiting for liver transplantation.
Authors: Paige Kaplan; Can Ficicioglu; Alice T Mazur; Michael J Palmieri; Gerard T Berry Journal: Mol Genet Metab Date: 2006-06-05 Impact factor: 4.797
Authors: Lisa C Worgan; Kirsten Niles; Jamie C Tirone; Adam Hofmann; Andrei Verner; Alya'a Sammak; Terrence Kucic; Pierre Lepage; David S Rosenblatt Journal: Hum Mutat Date: 2006-01 Impact factor: 4.878
Authors: Liise K Kayler; Robert M Merion; Samuel Lee; Randall S Sung; Jeffrey D Punch; Steven M Rudich; Jeremiah G Turcotte; Darrell A Campbell; Ronald Holmes; John C Magee Journal: Pediatr Transplant Date: 2002-08
Authors: I R Badell; S I Hanish; C B Hughes; W R Hewitt; R T Chung; J R Spivey; S J Knechtle Journal: Transplant Proc Date: 2012-09-06 Impact factor: 1.066
Authors: Femke Molema; Diego Martinelli; Friederike Hörster; Stefan Kölker; Trine Tangeraas; Barbara de Koning; Carlo Dionisi-Vici; Monique Williams Journal: J Inherit Metab Dis Date: 2020-10-29 Impact factor: 4.982